IRL 2500

• Description :

  IRL 2500 is a potent Endothelin receptor antagonist. IRL 2500 shows IC50 values of 1.3 and 94 nM for ETB and ETA receptors, respectively. IRL 2500 inhibits ETB receptor-mediated blood pressure increase and renal vascular resistance in rats in vivo[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Endothelin Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/irl-2500.html

• Purity :

  99.27

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(O)[C@H](CC1=CNC2=CC=CC=C12)NC([C@@H](CC3=CC=C(C4=CC=CC=C4)C=C3)N(C(C5=CC(C)=CC(C)=C5)=O)C)=O

• Molecular Formula :

  C36H35N3O4

• Molecular Weight :

  573.68

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Balwierczak JL, et al. Characterization of a potent and selective endothelin-B receptor antagonist, IRL 2500.J Cardiovasc Pharmacol. 1995;26 Suppl 3:S393-6.|[2]Webb RL, et al. Effects of the ETB-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats.J Cardiovasc Pharmacol. 1995;26 Suppl 3:S389-92.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  ETA; ETB

• CAS Number :

  [169545-27-1]